CHANCE-2 Study

The purpose of the Carolina Head and Neck Cancer Study (CHANCE-2) is to understand how the characteristics of a head and neck cancer patient and their tumor influence prognosis, treatment, and outcome.

Background

Traditionally associated with heavy smoking and alcohol consumption, it is estimated that approximately 60-70% of new oropharyngeal squamous cell carcinoma (OPSCC) cases are attributed to human papilloma virus (HPV).

To date, there are no population-based studies or tumor registries that incorporate HPV status in head and neck cancer. The Carolina Head and Neck Cancer Study, CHANCE-2, will provide the first comprehensive population-based resource to examine molecular heterogeneity among HPV+ and HPV- tumors from head and neck cancer patients and their outcomes.

Study Design

Within the six-year time span between 2018-2024, the CHANCE-2 team will:

1. Interview up to 1,800 men and women with head and neck squamous cell carcinoma (HNSCC) living in 46 counties in North Carolina. From volunteers, researchers will collect demographic and risk factor data through telephone surveys.
2. Collect medical records to obtain diagnosis, treatment, follow-up, and outcome information.
3. Request tumor samples and test them to determine HPV status and molecular subtypes and mutational profile.
4. Re-contact participants at one-year and three-years post-diagnosis to obtain updated treatment information.

For a full searchable list of counties included in the study area, click or select here

What makes CHANCE-2 possible?

CHANCE-2 is possible because of the dedication, determination, generosity, and advocacy of the People of North Carolina.

CHANCE-2 is conducted by the Lineberger Comprehensive Cancer Center in affiliation with the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. This study is funded by the University Cancer Research Fund, and additional funding was provided by Dr. Neil Hayes, University of Tennessee Health Science Center.